title: Cementless total hip arthroplasty in Paget's disease of bone: a retrospective review.
abstract: Paget's disease of bone (PDB) is a localised chronic osteopathy leading to bone deformities, bone hypervascularity, structural weakness and altered joint biomechanics. The pelvis and upper femur are frequently involved, resulting in disabling hip disease, and total hip arthroplasty (THA) may be required. We performed a retrospective study on the management and the outcome of 39 uncemented hydroxyapatite fully-coated THA in patients with PDB of the hip. The follow-up averaged 79.4 months (range 24-194). Functional scores improved significantly and, using the Harris hip score, 84% of patients had an excellent clinical outcome at the latest follow-up. Despite one case of an uncemented acetabular component with probable loosening, no implant revision had been required at our latest follow-up. Signs of implant loosening were found to be significantly more frequent in patients with active disease. For this reason, we advocate the use of pre-operative medication with bisphosphonates to reduce disease activity. Another benefit of this treatment is the significant decrease of intra-operative blood loss. Provided the control of disease activity in the pre-operative period with bisphosphonates is achieved, good outcome of cementless THAs can be expected. Bisphosphonates reduced the risk of implant loosening and excessive intra-operative blood loss.
authors: Department of Orthopedic Surgery - Pavillon T, Hôpital Edouard Herriot, Lyon, France. julien.wegrzyn@chu-lyon.fr
authors: Julien
authors: J
authors: Wegrzyn
authors: Vincent
authors: V
authors: Pibarot
authors: Roland
authors: R
authors: Chapurlat
authors: Jean-Paul
authors: JP
authors: Carret
authors: Jacques
authors: J
authors: Béjui-Hugues
authors: Olivier
authors: O
authors: Guyen
mesh_terms: D000203:Activities of Daily Living; D000368:Aged; D000369:Aged, 80 and over; D019644:Arthroplasty, Replacement, Hip / Q000379:methods* / Q000534:rehabilitation; D050071:Bone Density Conservation Agents / Q000627:therapeutic use; D002484:Cementation; D004164:Diphosphonates / Q000627:therapeutic use; D017886:Durapatite; D005260:Female; D006305:Health Status Indicators; D006621:Hip Joint / Q000503:physiopathology / Q000601:surgery*; D006622:Hip Prosthesis; D006801:Humans; D008297:Male; D008875:Middle Aged; D010001:Osteitis Deformans / Q000601:surgery*; D011183:Postoperative Complications; D011300:Preoperative Care; D011475:Prosthesis Failure / Q000187:drug effects; D016059:Range of Motion, Articular; D012086:Reoperation; D012189:Retrospective Studies; D016896:Treatment Outcome
chemical_list: D050071:Bone Density Conservation Agents; D004164:Diphosphonates; D017886:Durapatite